Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the ...

FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the NYSE in New York (Reuters) -Abbott Laboratories will stop sales of its Similac Probiotic Tri-Blend product used for hospitalized ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has agreed to discontinue sales of its ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to invest ...

A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories (NYSE:ABT) regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, ...

Santa Ana-based Abbott Medical Optics Inc. is readying a product push. The maker of eye surgery devices, part of Chicago-area drug and medical device maker Abbott Laboratories, has plans for 20 new ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories CEO Robert Ford adamantly defended the ...